Silo Pharma logo

Silo PharmaNASDAQ: SILO

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

08 January 2021

Next earnings report:

N/A

Last dividends:

N/A

Next dividends:

N/A
$2.75 M
-88%vs. 3y high
7%vs. sector
-vs. 3y high
-vs. sector
-91%vs. 3y high
27%vs. sector
-94%vs. 3y high
89%vs. sector

Price

after hours | Wed, 03 Jul 2024 20:15:33 GMT
$0.98+$0.03(+3.69%)

Dividend

No data over the past 3 years
$18.00 K-$801.70 K

Analysts recommendations

Institutional Ownership

SILO Latest News

Silo Pharma Announces Successful Production of its SP-26 Ketamine Implant for Fibromyalgia
globenewswire.com07 June 2024 Sentiment: POSITIVE

Analytical testing has confirmed optimal formulation for upcoming studies SARASOTA, FL, June 07, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today announced a successful series of development activities for the Company's SP-26 ketamine implant therapeutic targeting fibromyalgia and chronic pain. An ongoing pre-clinical research study of SP-26 is underway involving analytical testing services and small batch proof-of-concept extrusion trials for the ketamine hydrochloride (ketamine HCL) implants at 20% and 40% drug load.

Silo Pharma shares take off as anxiety and PTSD therapeutic candidate achieves milestone
Proactive Investors08 August 2023 Sentiment: POSITIVE

Silo Pharma shares rose on Tuesday after the development stage biopharmaceutical company announced it has advanced the formulation development of its therapeutic candidate SPC-15, achieving a liquid nasal formulation. This formulation of SPC-15, a targeted prophylactic treatment using ketamine compositions, is being investigated as a method of treatment and prevention of anxiety, post-traumatic stress disorder (PTSD) and other stress disorders.

What type of business is Silo Pharma?

Silo Pharma, Inc. operates as a developmental stage biopharmaceutical company. The company focuses on merging traditional therapeutics with psychedelic research for patients with depression, post-traumatic stress disorder, Alzheimer's, Parkinson's, and other rare neurological disorders. It has a scientific research agreement with the University of Maryland, The Regents of the University of California, and Columbia University. The company was formerly known as Uppercut Brands, Inc. and changed its name to Silo Pharma, Inc. in September 2020. Silo Pharma, Inc. was incorporated in 2010 and is headquartered in Englewood Cliffs, New Jersey.

What sector is Silo Pharma in?

Silo Pharma is in the Healthcare sector

What industry is Silo Pharma in?

Silo Pharma is in the Biotechnology industry

What country is Silo Pharma from?

Silo Pharma is headquartered in United States

When did Silo Pharma go public?

Silo Pharma initial public offering (IPO) was on 08 January 2021

What is Silo Pharma website?

https://silopharma.com

Is Silo Pharma in the S&P 500?

No, Silo Pharma is not included in the S&P 500 index

Is Silo Pharma in the NASDAQ 100?

No, Silo Pharma is not included in the NASDAQ 100 index

Is Silo Pharma in the Dow Jones?

No, Silo Pharma is not included in the Dow Jones index

When does Silo Pharma report earnings?

Next earnings report date is not announced yet